PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients …
…, KH Kuck, SH Ostermayer, F Büscheck… - … : journal of EuroPCR …, 2010 - europepmc.org
Aims The European PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion)
study was performed to determine the safety and efficacy of left atrial appendage occlusion …
study was performed to determine the safety and efficacy of left atrial appendage occlusion …
Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder)
…, M Leetz, R Hein, Y Bayard, F Büscheck… - The American journal of …, 2008 - Elsevier
This randomized trial compared procedural complications and 30-day clinical outcomes of 3
patent foramen ovale (PFO) closure devices (Amplatzer, Helex, and CardioSEAL-STARflex)…
patent foramen ovale (PFO) closure devices (Amplatzer, Helex, and CardioSEAL-STARflex)…
[HTML][HTML] Random forest-based modelling to detect biomarkers for prostate cancer progression
R Toth, H Schiffmann, C Hube-Magg, F Büscheck… - Clinical …, 2019 - Springer
Background The clinical course of prostate cancer (PCa) is highly variable, demanding an
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …
[HTML][HTML] p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors
S Steurer, C Riemann, F Büscheck, AM Luebke… - Biomarker …, 2021 - Springer
… Franziska Büscheck …
[HTML][HTML] Up-regulation of biglycan is associated with poor prognosis and PTEN deletion in patients with prostate cancer
…, A Hinsch, W Wilczak, C Wittmer, F Büscheck… - Neoplasia, 2017 - Elsevier
Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures
for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its …
for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its …
[HTML][HTML] Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
…, C Yang, JB Raedler, R Simon, F Büscheck… - Cellular Oncology, 2021 - Springer
Purpose Expansion of CD8 + cytotoxic Tlymphocytes is a prerequisite for anti-cancer immune
activity and has gained interest in the era of immune checkpoint therapy. Methods To …
activity and has gained interest in the era of immune checkpoint therapy. Methods To …
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA …
…, C Hube-Magg, M Kluth, R Simon, F Büscheck… - …, 2017 - academic.oup.com
DNA mismatch repair (MMR) is integral to the maintenance of genetic stability. We aimed to
evaluate the clinical impact of MMR gene expression in prostate cancer. The MMR genes …
evaluate the clinical impact of MMR gene expression in prostate cancer. The MMR genes …
Marked prognostic impact of minimal lymphatic tumor spread in prostate cancer
…, T Clauditz, S Minner, S Steurer, F Büscheck… - European urology, 2018 - Elsevier
Background Nodal metastasis (N1) is a strong prognostic parameter in prostate cancer;
however, lymph node evaluation is always incomplete. Objective To study the prognostic value …
however, lymph node evaluation is always incomplete. Objective To study the prognostic value …
[HTML][HTML] Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors
A Menz, T Weitbrecht, N Gorbokon, F Büscheck… - Molecular …, 2021 - Springer
Background Cytokeratin 18 (CK18) is an intermediate filament protein of the cytokeratin acidic
type I group and is primarily expressed in single-layered or “simple” epithelial tissues and …
type I group and is primarily expressed in single-layered or “simple” epithelial tissues and …
[HTML][HTML] Patterns of TIGIT expression in lymphatic tissue, inflammation, and cancer
…, G Sauter, JR Izbicki, S Minner, F Büscheck… - Disease …, 2019 - hindawi.com
TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune
therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and …
therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and …